AntriaBio

AntriaBio is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
Type
Public
HQ
Louisville, US
Founded
2010
Size (employees)
19 (est)
AntriaBio was founded in 2010 and is headquartered in Louisville, US

AntriaBio Office Locations

AntriaBio has office in Louisville
Louisville, US

AntriaBio Metrics

AntriaBio Summary

Market capitalization

$36.9 M

Closing share price

$0.95
AntriaBio's current market capitalization is $36.9 M.

AntriaBio Market Value History

We estimate that AntriaBio's current employees are approximately 21% female and 79% male.

AntriaBio Online Presence

AntriaBio Company Life

You may also be interested in